India’s position as a global pharmaceutical powerhouse is facing intense domestic scrutiny as the persistent flow of counterfeit and substandard medicines continues to threaten public health. Despite supplying critical generics worldwide, the country still lacks a centralized national database to track illnesses and deaths caused by spurious drugs. This regulatory gap leaves public health officials unable to measure the true scale of the crisis, allowing dangerous products to circulate undetected in the domestic market.
The Hidden Toll of Substandard Medicines
While India’s pharmaceutical sector produces over 20 percent of the world’s generic medicines, domestic supply chains remain highly vulnerable to infiltration. Without a unified reporting system, tracking the human cost of counterfeit pharmaceuticals is nearly impossible. Most incidents of drug-related harm go completely unrecorded, leaving families without answers and regulators without actionable data.
The World Health Organization (WHO) estimates that approximately one in ten medical products in low- and middle-income countries is either substandard or falsified. In India, government-led sampling surveys often place the prevalence of spurious drugs at less than five percent. However, independent health advocates argue these figures underrepresent the reality in rural and semi-urban pharmacies, where regulatory oversight is sparse.
The lack of systematic pharmacovigilance—the practice of monitoring the effects of medical drugs—means that contaminated or ineffective pills are often only discovered after a major tragedy occurs. When a patient fails to recover, doctors routinely attribute the outcome to the progression of the disease rather than questioning the integrity of the medicine itself.
Expert Warning on Systemic Blind Spots
The systemic nature of this crisis has drawn sharp criticism from former high-ranking regulatory officials. Najib Shah, the former Chairman of the Central Board of Indirect Taxes and Customs (CBIC), recently highlighted how the lack of data shields the counterfeit industry. He noted that only highly publicized, tragic incidents manage to link patient deaths directly to contaminated medicines.
“There is no national database of death and illness caused by spurious or substandard drugs,” Shah stated. He warned that unless a direct cause-and-effect relationship is proven in a court of law, the vast majority of cases “go unnoticed, unreported.” This lack of documentation severely hampers law enforcement and customs agencies from targeting the syndicates manufacturing these illicit products.
Legal experts also point out that prosecution rates for manufacturing counterfeit drugs remain low. The judicial process is often slow, and proving intent or direct harm in a fragmented supply chain presents immense evidentiary challenges for prosecutors, who must trace the chemical origin of the seized products back to illegal labs.
A Fragmented Regulatory Landscape
The root of India’s enforcement challenge lies in its decentralized regulatory framework. The Central Drugs Standard Control Organisation (CDSCO) shares licensing and enforcement powers with individual state drug control administrations. This division of labor often results in inconsistent standards, varying laboratory testing capacities, and delayed communication during drug recalls.
When a state laboratory identifies a drug batch as “Not of Standard Quality” (NSQ), there is no automated mechanism to immediately halt sales in neighboring states. Consequently, recalled products can remain on pharmacy shelves for weeks, continuing to pose a risk to unsuspecting consumers who purchase them over the counter.
Industry analysts emphasize that the lack of coordination allows unscrupulous manufacturers to exploit regulatory arbitrage. Companies penalized in one state can sometimes continue operations by shifting their focus or distribution networks to states with less stringent oversight, compounding the difficulty of nationwide enforcement.
Technological Solutions and Future Outlook
To address these vulnerabilities, the Indian government has initiated several tech-driven reforms. Recently, the Ministry of Health mandated the use of Quick Response (QR) codes on the packaging of the top 300 drug brands. This measure aims to allow consumers and retailers to verify the authenticity of medicines instantly using their smartphones.
While experts welcome the QR code initiative, they argue that technology alone cannot solve a structural enforcement problem. True reform will require upgrading state testing laboratories, increasing the number of drug inspectors, and implementing a mandatory national registry for all adverse drug reactions.
Moving forward, the focus will shift to how effectively India can harmonize its state-level regulations and enforce trace-and-track laws across the entire supply chain. Watchdogs and international partners will closely monitor whether the government establishes a centralized database to finally bring transparency to drug-related casualties. Until these systemic gaps are closed, the battle against counterfeit medicines will remain an uphill struggle for the world’s pharmacy.
